How big is the Europe Biologics Market?

The Europe Biologics Market is valued at US$ 1,15,057.6 Million in 2023, it is projected to reach US$ 4,15,468.4 Million by 2031.

What is the CAGR for Europe Biologics Market by (2023 - 2031)?

As per our report Europe Biologics Market, the market size is valued at US$ 1,15,057.6 Million in 2023, projecting it to reach US$ 4,15,468.4 Million by 2031. This translates to a CAGR of approximately 17.4% during the forecast period.

What segments are covered in this report?

The Europe Biologics Market report typically cover these key segments- 产品（单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等）应用（癌症、传染病、自身免疫性疾病等）来源（哺乳动物和微生物）

What is the historic period, base year, and forecast period taken for Europe Biologics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Biologics Market report: 2025-2031 2023 2021-2023

Who are the major players in Europe Biologics Market?

The Europe Biologics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include: AbbVie Inc ; Pfizer Inc ; Samsung Biologics Co Ltd ; ADMA Biologics, Inc. ; Wuxi Biologics Inc ; Catalent Inc ; AGC Biologics AS ; AstraZeneca Plc ; Amgen Inc ; Nitto Avecia ; Quality Assistance s.a.

Who should buy this report?

The Europe Biologics Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the Europe Biologics Market value chain can benefit from the information contained in a comprehensive market report.

欧洲生物制剂市场（主要地区、市场参与者、规模和份额）- 预测至 2031 年

2023 年欧洲生物制剂市场价值为 1150.576 亿美元，预计到 2031 年将达到 4154.684 亿美元；预计 2023 年至 2031 年的复合年增长率为 17.4%。

对外包制造业务的偏好推动欧洲生物制剂市场

生物制剂制造是一个复杂的过程，其成功取决于所有操作的正确执行和监控。制造设施需要训练有素、具备生物加工和工艺工程技术知识的人员。对于经验丰富的团队来说，管理使用手动和开放式制造方法进行首次临床试验的尝试，然后构建更适合商业化的工艺可能会很棘手。因此，制造商选择与合同开发和制造组织 (CDMO) 合作，以加速其临床研究和商业化运营。CDMO 以合同方式向生物制剂公司提供产品开发、临床试验支持、制造和商业化服务。与CDMO合作，可以实现可扩展性，并在无需支付管理费用的情况下获得技术专长，同时加快产品上市速度并提高生物制剂制造商的成本效益。2022年4月，ThermoGenesis在美国加利福尼亚州建立了自己的CDMO工厂，为细胞和基因治疗制造商提供CDMO服务。利用其专业知识，该公司专注于生产嵌合抗原受体T细胞（CAR-T细胞）、T细胞受体（TCR）、肿瘤浸润白细胞（TIL）、自然杀伤细胞（NK）、诱导多能干细胞（iPSC）和间充质干细胞（MSC）。事实证明，将生物制剂生产外包给CDMO对制造商而言具有成本效益。此外，他们还可以获得CDMO技术先进的基础设施和专业知识。CDMO采用适当的、规划好的流程来生产生物制剂。因此，将生物制剂生产业务外包给CDMO的趋势日益高涨，推动了生物制剂市场的增长。

欧洲生物制剂市场概览

欧洲的生物制剂市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。欧洲拥有第二大市场份额，这可以归因于不断增加的癌症负担和癌症诊断技术的进步，有助于早期发现。单克隆抗体在各种研发应用、癌症治疗和免疫疾病中的日益增长的使用也促进了欧洲生物制剂市场的进步。在欧盟 (EU) 所有国家中，德国对医疗保健研究和基础设施的投资最大。根据欧盟统计局的数据，2015 年德国的医疗保健支出为 3.949 亿美元，是该地区相关国家中最高的之一。根据 2015 年经合组织卫生统计数据，德国的医疗支出增长速度快于经合组织预测的实际平均水平；这可能与为支持药品开发、研究和制造而投入的资本增加有关。因此，医疗保健行业强劲的资金支持增强了德国生物制剂市场。

欧洲生物制剂市场收入及预测至 2031 年（百万美元）

欧洲生物制剂市场细分

欧洲生物制剂市场分为产品、应用、来源、制造和国家。

根据产品，欧洲生物制剂市场细分为单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等。单克隆抗体细分市场在 2023 年占据最大市场份额。

根据应用，欧洲生物制剂市场分为癌症、传染病、自身免疫性疾病等。癌症细分市场在 2023 年占据最大市场份额。

按来源，欧洲生物制剂市场分为哺乳动物和微生物。 2023 年，哺乳动物细分市场占有更大的市场份额。

根据制造方式，欧洲生物制剂市场分为外包和内部制造。2023 年，外包细分市场占有更大的市场份额。

按国家/地区划分，欧洲生物制剂市场分为德国、英国、意大利、法国、西班牙和欧洲其他地区。2023 年，德国占据了欧洲生物制剂市场的主导地位。

AbbVie Inc、Pfizer Inc、Samsung Biologics Co Ltd、ADMA Biologics, Inc.、Wuxi Biologics Inc、Catalent Inc、AGC Biologics AS、AstraZeneca Plc、Amgen Inc、Nitto Avecia 和 Quality Assistance sa 是欧洲生物制剂市场的一些领先公司。

Europe Biologics Strategic Insights

Strategic insights for Europe Biologics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-biologics-market-strategic-framework.webp

Get more information on this report

Europe Biologics Report Scope

Report Attribute	Details
Market size in 2023	US$ 1,15,057.6 Million
Market Size by 2031	US$ 4,15,468.4 Million
Global CAGR (2023 - 2031)	17.4%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 产品（单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等） By 应用（癌症、传染病、自身免疫性疾病等） By 来源（哺乳动物和微生物） By 制造（外包和内部）
Regions and Countries Covered	欧洲（德国、英国、法国、意大利、西班牙、欧洲其他地区）欧洲（德国、英国、法国、意大利、西班牙、欧洲其他地区）
Market leaders and key company profiles	AbbVie Inc Pfizer Inc Samsung Biologics Co Ltd ADMA Biologics, Inc. Wuxi Biologics Inc Catalent Inc AGC Biologics AS AstraZeneca Plc Amgen Inc Nitto Avecia

Get more information on this report

Europe Biologics Regional Insights

The regional scope of Europe Biologics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.